{"pmid":32460383,"title":"Fighting COVID-19, a Place for Artificial Intelligence.","text":["Fighting COVID-19, a Place for Artificial Intelligence.","The emergence of the coronavirus disease 2019 (COVID-19) heralded a new era in the cross-species transmission of severe respiratory illness leading to rapid spread in mainland China and around the world with a case fatality rate of 2.3% in China and 1.8-7.2% outside China (Wu & McGoogan, 2019; Centers for Disease Control and Prevention, 2020; Onder Rezza, & Brusaferro, 2020; World Health Organization, 2020). As of May 15, 2020, a total of 4,338,658 confirmed cases of COVID-19 and 297,119 death cases have been documented globally (World Health Organization, 2020). Several strategies have been adopted to contain the outbreak including classic infection-control and public health measures, nevertheless these measures may not be effective for tackling the scale of COVID-19.","Transbound Emerg Dis","Emile, Sameh Hany","Hamid, Hytham K S","32460383"],"abstract":["The emergence of the coronavirus disease 2019 (COVID-19) heralded a new era in the cross-species transmission of severe respiratory illness leading to rapid spread in mainland China and around the world with a case fatality rate of 2.3% in China and 1.8-7.2% outside China (Wu & McGoogan, 2019; Centers for Disease Control and Prevention, 2020; Onder Rezza, & Brusaferro, 2020; World Health Organization, 2020). As of May 15, 2020, a total of 4,338,658 confirmed cases of COVID-19 and 297,119 death cases have been documented globally (World Health Organization, 2020). Several strategies have been adopted to contain the outbreak including classic infection-control and public health measures, nevertheless these measures may not be effective for tackling the scale of COVID-19."],"journal":"Transbound Emerg Dis","authors":["Emile, Sameh Hany","Hamid, Hytham K S"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32460383","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/tbed.13648","locations":["China","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1668141322668605441,"score":9.490897,"similar":[{"pmid":32420610,"title":"Temporal Changes in Immune Blood Cell Parameters in COVID-19 Infection and Recovery from Severe Infection.","text":["Temporal Changes in Immune Blood Cell Parameters in COVID-19 Infection and Recovery from Severe Infection.","Since emerging in China in December 2019, the infection caused by SARS-CoV-2, COVID-19, has infected more than 3 million people worldwide (Johns Hopkins University and Medicine: Coronavirus Resource Center). Since then, clusters of infections have emerged in Singapore, particularly among younger workers in communal living environments. The spectrum of COVID-19 infection ranges from mild respiratory illness, to viral pneumonia and life-threatening acute respiratory distress syndrome in up 15-20% (Huang, et al 2020, Wu and McGoogan 2020).","Br J Haematol","Yip, Christina Yc","Yap, Eng Soo","Mel, Sanjay De","Teo, Winnie Z Y","Lee, Chun-Tsu","Kan, Sheryl","Lee, Chang Chuan Melvin","Loh, Will Nh","Lim, Er Luen","Lee, Shir Ying","32420610"],"abstract":["Since emerging in China in December 2019, the infection caused by SARS-CoV-2, COVID-19, has infected more than 3 million people worldwide (Johns Hopkins University and Medicine: Coronavirus Resource Center). Since then, clusters of infections have emerged in Singapore, particularly among younger workers in communal living environments. The spectrum of COVID-19 infection ranges from mild respiratory illness, to viral pneumonia and life-threatening acute respiratory distress syndrome in up 15-20% (Huang, et al 2020, Wu and McGoogan 2020)."],"journal":"Br J Haematol","authors":["Yip, Christina Yc","Yap, Eng Soo","Mel, Sanjay De","Teo, Winnie Z Y","Lee, Chun-Tsu","Kan, Sheryl","Lee, Chang Chuan Melvin","Loh, Will Nh","Lim, Er Luen","Lee, Shir Ying"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420610","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/bjh.16847","locations":["China","Singapore"],"countries":["Singapore","China"],"countries_codes":["SGP|Singapore","CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1667254896774086656,"score":165.11757},{"pmid":32419771,"pmcid":"PMC7225708","title":"[Epidemiological Aspects, Clinic And Control Mechanisms Of Sars-Cov-2pandemic: Situation In Spain].","text":["[Epidemiological Aspects, Clinic And Control Mechanisms Of Sars-Cov-2pandemic: Situation In Spain].","In January 2020, the Chinese authorities confirmed the causative agent of an outbreak of cases with pneumonia of unknown etiology that appeared in December 2019. The World Health Organization (WHO) called COVID-19 is a new virus of the coronavirus family. On March 12, the WHO declared this outbreak as a pandemic as it spread worldwide. Human epidemics usually follow the start of exponential growth, this means that from a small number of cases in a few days, a large increase in the number of infected people is observed. The clinical manifestations and spectrum of symptomatic disease range from moderate to critical presentations. In cases with fatal progression, the most serious complications sometimes are cause of a multi-organ failure and patient death. SARS-CoV-2 has a high transmission rate, the route of transmission between humans is through the secretions of infected people, hands or contaminated objects. In general, the epidemic control measures used so far have been based on adoption of interventions from the classical epidemiology, identifying and isolating the cases, following the contacts and establishing restrictions, including quarantine, closure of educational centers, avoiding events in which crowds of people occur, limiting mobility. These measures have been effective in China, the original focus of the outbreak.","Enferm Clin","Garcia-Alamino, Josep M feminine","32419771"],"abstract":["In January 2020, the Chinese authorities confirmed the causative agent of an outbreak of cases with pneumonia of unknown etiology that appeared in December 2019. The World Health Organization (WHO) called COVID-19 is a new virus of the coronavirus family. On March 12, the WHO declared this outbreak as a pandemic as it spread worldwide. Human epidemics usually follow the start of exponential growth, this means that from a small number of cases in a few days, a large increase in the number of infected people is observed. The clinical manifestations and spectrum of symptomatic disease range from moderate to critical presentations. In cases with fatal progression, the most serious complications sometimes are cause of a multi-organ failure and patient death. SARS-CoV-2 has a high transmission rate, the route of transmission between humans is through the secretions of infected people, hands or contaminated objects. In general, the epidemic control measures used so far have been based on adoption of interventions from the classical epidemiology, identifying and isolating the cases, following the contacts and establishing restrictions, including quarantine, closure of educational centers, avoiding events in which crowds of people occur, limiting mobility. These measures have been effective in China, the original focus of the outbreak."],"journal":"Enferm Clin","authors":["Garcia-Alamino, Josep M feminine"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32419771","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.enfcli.2020.05.001","locations":["Chinese","China","Spain"],"countries":["Spain","China"],"countries_codes":["ESP|Spain","CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1667254896730046465,"score":152.20956},{"pmid":32027631,"pmcid":"PMC7004396","title":"Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020.","text":["Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020.","On December 31, 2019, Chinese health officials reported a cluster of cases of acute respiratory illness in persons associated with the Hunan seafood and animal market in the city of Wuhan, Hubei Province, in central China. On January 7, 2020, Chinese health officials confirmed that a novel coronavirus (2019-nCoV) was associated with this initial cluster (1). As of February 4, 2020, a total of 20,471 confirmed cases, including 2,788 (13.6%) with severe illness,* and 425 deaths (2.1%) had been reported by the National Health Commission of China (2). Cases have also been reported in 26 locations outside of mainland China, including documentation of some person-to-person transmission and one death (2). As of February 4, 11 cases had been reported in the United States. On January 30, the World Health Organization (WHO) Director-General declared that the 2019-nCoV outbreak constitutes a Public Health Emergency of International Concern.(dagger) On January 31, the U.S. Department of Health and Human Services (HHS) Secretary declared a U.S. public health emergency to respond to 2019-nCoV.( section sign) Also on January 31, the president of the United States signed a \"Proclamation on Suspension of Entry as Immigrants and Nonimmigrants of Persons who Pose a Risk of Transmitting 2019 Novel Coronavirus,\" which limits entry into the United States of persons who traveled to mainland China to U.S. citizens and lawful permanent residents and their families (3). CDC, multiple other federal agencies, state and local health departments, and other partners are implementing aggressive measures to slow transmission of 2019-nCoV in the United States (4,5). These measures require the identification of cases and their contacts in the United States and the appropriate assessment and care of travelers arriving from mainland China to the United States. These measures are being implemented in anticipation of additional 2019-nCoV cases in the United States. Although these measures might not prevent the eventual establishment of ongoing, widespread transmission of the virus in the United States, they are being implemented to 1) slow the spread of illness; 2) provide time to better prepare health care systems and the general public to be ready if widespread transmission with substantial associated illness occurs; and 3) better characterize 2019-nCoV infection to guide public health recommendations and the development of medical countermeasures including diagnostics, therapeutics, and vaccines. Public health authorities are monitoring the situation closely. As more is learned about this novel virus and this outbreak, CDC will rapidly incorporate new knowledge into guidance for action by CDC and state and local health departments.","MMWR Morb Mortal Wkly Rep","Patel, Anita","Jernigan, Daniel B","32027631"],"abstract":["On December 31, 2019, Chinese health officials reported a cluster of cases of acute respiratory illness in persons associated with the Hunan seafood and animal market in the city of Wuhan, Hubei Province, in central China. On January 7, 2020, Chinese health officials confirmed that a novel coronavirus (2019-nCoV) was associated with this initial cluster (1). As of February 4, 2020, a total of 20,471 confirmed cases, including 2,788 (13.6%) with severe illness,* and 425 deaths (2.1%) had been reported by the National Health Commission of China (2). Cases have also been reported in 26 locations outside of mainland China, including documentation of some person-to-person transmission and one death (2). As of February 4, 11 cases had been reported in the United States. On January 30, the World Health Organization (WHO) Director-General declared that the 2019-nCoV outbreak constitutes a Public Health Emergency of International Concern.(dagger) On January 31, the U.S. Department of Health and Human Services (HHS) Secretary declared a U.S. public health emergency to respond to 2019-nCoV.( section sign) Also on January 31, the president of the United States signed a \"Proclamation on Suspension of Entry as Immigrants and Nonimmigrants of Persons who Pose a Risk of Transmitting 2019 Novel Coronavirus,\" which limits entry into the United States of persons who traveled to mainland China to U.S. citizens and lawful permanent residents and their families (3). CDC, multiple other federal agencies, state and local health departments, and other partners are implementing aggressive measures to slow transmission of 2019-nCoV in the United States (4,5). These measures require the identification of cases and their contacts in the United States and the appropriate assessment and care of travelers arriving from mainland China to the United States. These measures are being implemented in anticipation of additional 2019-nCoV cases in the United States. Although these measures might not prevent the eventual establishment of ongoing, widespread transmission of the virus in the United States, they are being implemented to 1) slow the spread of illness; 2) provide time to better prepare health care systems and the general public to be ready if widespread transmission with substantial associated illness occurs; and 3) better characterize 2019-nCoV infection to guide public health recommendations and the development of medical countermeasures including diagnostics, therapeutics, and vaccines. Public health authorities are monitoring the situation closely. As more is learned about this novel virus and this outbreak, CDC will rapidly incorporate new knowledge into guidance for action by CDC and state and local health departments."],"journal":"MMWR Morb Mortal Wkly Rep","authors":["Patel, Anita","Jernigan, Daniel B"],"date":"2020-02-07T11:00:00Z","year":2020,"_id":"32027631","source":"PubMed","week":"20206|Feb 03 - Feb 09","doi":"10.15585/mmwr.mm6905e1","link_erratum_in":"32053580","locations":["Chinese","Hunan","Wuhan","Hubei","China","Chinese","China","United States","USA","United States","United States","China","USA","United States","United States","China","United States","United States","United States"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1666138493034692610,"score":147.25401},{"pmid":32106216,"title":"Update: Public Health Response to the Coronavirus Disease 2019 Outbreak - United States, February 24, 2020.","text":["Update: Public Health Response to the Coronavirus Disease 2019 Outbreak - United States, February 24, 2020.","An outbreak of coronavirus disease 2019 (COVID-19) caused by the 2019 novel coronavirus (SARS-CoV-2) began in Wuhan, Hubei Province, China in December 2019, and has spread throughout China and to 31 other countries and territories, including the United States (1). As of February 23, 2020, there were 76,936 reported cases in mainland China and 1,875 cases in locations outside mainland China (1). There have been 2,462 associated deaths worldwide; no deaths have been reported in the United States. Fourteen cases have been diagnosed in the United States, and an additional 39 cases have occurred among repatriated persons from high-risk settings, for a current total of 53 cases within the United States. This report summarizes the aggressive measures (2,3) that CDC, state and local health departments, multiple other federal agencies, and other partners are implementing to slow and try to contain transmission of COVID-19 in the United States. These measures require the identification of cases and contacts of persons with COVID-19 in the United States and the recommended assessment, monitoring, and care of travelers arriving from areas with substantial COVID-19 transmission. Although these measures might not prevent widespread transmission of the virus in the United States, they are being implemented to 1) slow the spread of illness; 2) provide time to better prepare state and local health departments, health care systems, businesses, educational organizations, and the general public in the event that widespread transmission occurs; and 3) better characterize COVID-19 to guide public health recommendations and the development and deployment of medical countermeasures, including diagnostics, therapeutics, and vaccines. U.S. public health authorities are monitoring the situation closely, and CDC is coordinating efforts with the World Health Organization (WHO) and other global partners. Interim guidance is available at https://www.cdc.gov/coronavirus/index.html. As more is learned about this novel virus and this outbreak, CDC will rapidly incorporate new knowledge into guidance for action by CDC, state and local health departments, health care providers, and communities.","MMWR Morb Mortal Wkly Rep","Jernigan, Daniel B","32106216"],"abstract":["An outbreak of coronavirus disease 2019 (COVID-19) caused by the 2019 novel coronavirus (SARS-CoV-2) began in Wuhan, Hubei Province, China in December 2019, and has spread throughout China and to 31 other countries and territories, including the United States (1). As of February 23, 2020, there were 76,936 reported cases in mainland China and 1,875 cases in locations outside mainland China (1). There have been 2,462 associated deaths worldwide; no deaths have been reported in the United States. Fourteen cases have been diagnosed in the United States, and an additional 39 cases have occurred among repatriated persons from high-risk settings, for a current total of 53 cases within the United States. This report summarizes the aggressive measures (2,3) that CDC, state and local health departments, multiple other federal agencies, and other partners are implementing to slow and try to contain transmission of COVID-19 in the United States. These measures require the identification of cases and contacts of persons with COVID-19 in the United States and the recommended assessment, monitoring, and care of travelers arriving from areas with substantial COVID-19 transmission. Although these measures might not prevent widespread transmission of the virus in the United States, they are being implemented to 1) slow the spread of illness; 2) provide time to better prepare state and local health departments, health care systems, businesses, educational organizations, and the general public in the event that widespread transmission occurs; and 3) better characterize COVID-19 to guide public health recommendations and the development and deployment of medical countermeasures, including diagnostics, therapeutics, and vaccines. U.S. public health authorities are monitoring the situation closely, and CDC is coordinating efforts with the World Health Organization (WHO) and other global partners. Interim guidance is available at https://www.cdc.gov/coronavirus/index.html. As more is learned about this novel virus and this outbreak, CDC will rapidly incorporate new knowledge into guidance for action by CDC, state and local health departments, health care providers, and communities."],"journal":"MMWR Morb Mortal Wkly Rep","authors":["Jernigan, Daniel B"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32106216","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.15585/mmwr.mm6908e1","locations":["Wuhan","Hubei","China","China","United States","China","China","United States","United States","United States","United States","United States","United States","USA"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1666138492875309056,"score":146.32991},{"pmid":32336927,"pmcid":"PMC7179492","title":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Emergence, History, Basic and Clinical Aspects.","text":["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Emergence, History, Basic and Clinical Aspects.","In late December 2019, the world woke to a reality of a pandemic of Coronavirus Disease (COVID-19), elicited by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which belongs to a group of beta-coronavirus. The potential to cause life-threatening respiratory failure and rapid transmission puts COVID-19 in the list of Public Health Emergency of International Concern (PHEIC). In the last two decades, this is the 3(rd) deadliest Coronavirus pandemic, following SARS which lasted between 2002 and 2003 and Middle East Respiratory Syndrome (MERS) from 2012 till date. Globally and as of April 1(st) 2020, COVID-19 has affected 924,688 individuals in over 200 countries, causing 46,368 fatalities. While the SARS-CoV-2 originated in China with over 82,724 confirmed cases and more than 3000 deaths as at the time of writing this review, the rapid transmission of SARS-CoV-2 has resulted in exponential increase in the number of cases outside of China to about 10 times the report case and death in mainland China. SARS-CoV-2 is suspected to be zoonotic in nature as genetic studies have shown sequence similarity to viruses originating from bats. Extreme precautionary measures, such as curfew, shutting of borders and quarantining of individuals suspected to be infected have been instituted with immediate effect; however, due to individuals that are asymptomatic, uncontrolled human-to-human transmission has resulted in exponential infection rate and numerous loss of lives even with this lockdown measures. This review article summarizes the developing situation surrounding the SARS-CoV-2 pandemic with respect to its epidemiology, unique genomic structure, possible origins, transmission, pathogenesis, comparison with other deadly species of Coronaviruses (CoV) and emerging treatment strategies built on informed literature.","Saudi J Biol Sci","Al-Qahtani, Ahmed A","32336927"],"abstract":["In late December 2019, the world woke to a reality of a pandemic of Coronavirus Disease (COVID-19), elicited by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which belongs to a group of beta-coronavirus. The potential to cause life-threatening respiratory failure and rapid transmission puts COVID-19 in the list of Public Health Emergency of International Concern (PHEIC). In the last two decades, this is the 3(rd) deadliest Coronavirus pandemic, following SARS which lasted between 2002 and 2003 and Middle East Respiratory Syndrome (MERS) from 2012 till date. Globally and as of April 1(st) 2020, COVID-19 has affected 924,688 individuals in over 200 countries, causing 46,368 fatalities. While the SARS-CoV-2 originated in China with over 82,724 confirmed cases and more than 3000 deaths as at the time of writing this review, the rapid transmission of SARS-CoV-2 has resulted in exponential increase in the number of cases outside of China to about 10 times the report case and death in mainland China. SARS-CoV-2 is suspected to be zoonotic in nature as genetic studies have shown sequence similarity to viruses originating from bats. Extreme precautionary measures, such as curfew, shutting of borders and quarantining of individuals suspected to be infected have been instituted with immediate effect; however, due to individuals that are asymptomatic, uncontrolled human-to-human transmission has resulted in exponential infection rate and numerous loss of lives even with this lockdown measures. This review article summarizes the developing situation surrounding the SARS-CoV-2 pandemic with respect to its epidemiology, unique genomic structure, possible origins, transmission, pathogenesis, comparison with other deadly species of Coronaviruses (CoV) and emerging treatment strategies built on informed literature."],"journal":"Saudi J Biol Sci","authors":["Al-Qahtani, Ahmed A"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32336927","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.sjbs.2020.04.033","keywords":["covid-19","coronavirus","emergence","epidemiology","pandemic","review","sars-cov-2"],"locations":["China","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Transmission","Treatment"],"weight":1,"_version_":1666138494156668928,"score":135.97842}]}